Paper Details

  1. Home
  2. Paper Details

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia.

Author: AlexanderLynette, AlvaradoYesid, AndreeffMichael, BorthakurGautam, BurgerJan A, DaverNaval, DinardoCourtney D, EstrovZeev, Garcia-ManeroGuillermo, IssaGhayas C, JabbourElias, KadiaTapan M, KonoplevaMarina, MaJunsheng, MacaronWalid, MasarovaLucia, MillerDarla, Montalban-BravoGuillermo, NaingAung, NingJing, PemmarajuNaveen, PierceSherry, RavandiFarhad, SasakiKoji, ShortNicholas J, TakahashiKoichi

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study investigated the effectiveness of different combinations of immunotherapy drugs for treating relapsed or refractory acute myeloid leukemia (AML). The results showed that the combination of azacitidine, venetoclax, and gemtuzumab ozogamicin was most promising, achieving a 50% complete remission rate in patients who had never received venetoclax treatment.
Paper Details　
Original Abstract of the Article :
We conducted a phase Ib/II multi-arm, parallel cohort study to simultaneously evaluate various immunotherapeutic agents and combinations in relapsed/refractory acute myeloid leukemia (AML). Overall, 50 patients were enrolled into one of 6 arms: (A) single agent PF-04518600 (OX40 agonist monoclonal a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1080/10428194.2022.2062345

データ提供：米国国立医学図書館（NLM）

Multi-Arm Phase Ib/II Study: Exploring New Frontiers in Acute Myeloid Leukemia Treatment

Acute myeloid leukemia (AML), a type of cancer affecting the blood and bone marrow, is like a desert storm, sweeping through the body with fierce intensity. This study explores the use of immunotherapy in treating relapsed/refractory AML, searching for new weapons in the fight against this disease. It's like exploring a vast desert, searching for hidden oases that offer potential solutions.

Finding Hope in the Desert: Azacitidine + Venetoclax + GO Combination

The study evaluated multiple immunotherapeutic agents and combinations, like different oases in a desert landscape. Among them, the combination of azacitidine, venetoclax, and gemtuzumab ozogamicin (GO) emerged as a potential oasis, offering significant promise for AML patients. It's like finding a well-stocked oasis in the heart of a barren desert, offering a chance for survival.

A New Path Forward: Collaboration and Innovation

The study highlights the feasibility of multi-arm trials, allowing for the efficient evaluation of multiple therapies in a single trial. It's like mapping a new route through the desert, where collaboration and innovation lead to faster progress. This approach is crucial in the fast-evolving field of cancer treatment, where new therapies are constantly emerging.

Dr.Camel's Conclusion

This study showcases the potential of immunotherapy to revolutionize AML treatment. It's like discovering a hidden spring in a desert, offering a refreshing new approach. While the journey towards effective treatments continues, this research offers hope for a future where AML is no longer a devastating diagnosis. It's a reminder that even in the harshest landscapes, innovation and collaboration can lead to remarkable breakthroughs.

Date :
  1. Date Completed 2022-10-10
  2. Date Revised 2022-11-16
Further Info :

Pubmed ID

35442137

DOI: Digital Object Identifier

10.1080/10428194.2022.2062345

Related Literature

Article Analysis
・Effects of glasdegib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.